A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice

Nature Genetics

Volumn 9, Issue 3, 1995, Pages 305-311

  Harvey, Michele ^a   Vogel, Hannes ^a   Morris, Danna ^a   Bradley, Allan ^a   Bernstein, Alan ^b   Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL GROWTH; EMBRYO; GENE MUTATION; HETEROZYGOSITY; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMAL; BASE SEQUENCE; CELL DIVISION; CROSSES, GENETIC; DNA PRIMERS; EMBRYO; FEMALE; FIBROBLASTS; GENE DELETION; GENES, P53; HETEROZYGOTE; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; POINT MUTATION; POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028842340     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0395-305     Document Type: Article

References (50)

1. Mowat, M., Cheng, A., Kimura, N., Bernstein, A. & Benchimol, S. Rearrangements of the Cellular p53 gene In erythroleukemic cells transformed by Friend virus. Nature 314, 633-636 (1985).
2. Ben-David, Y. & Bernstein, A. Friend virus-induced erythroleukaemia and the multistage nature of cancer. Cell 66, 831-834 (1991).
3. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 252, 49-53 (1991).
4. Greenblatt, M.S., Bennett, W.P., Hollstein, M. & Harris, C.C. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878 (1994).
5. Lane, D.P. p53 and human cancers. B. Med. Bull. 50, 582-599 (1994).
6. Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. & Cline, M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. natn. Acad. Scl. U.S.A. 84, 7716-7719 (1987).
7. Nigro, J.M. et al. Mutations in the p53 gene occur in diverse tumour types. Nature 342, 705-708 (1989).
8. Caron de Fromentel, C. & Soussi, T. TP53 tumour suppressor gene: A model for investigating human mutagenesis. Genes, Chrom. Cancer 4, 1-15 (1992).
9. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumour suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355 (1994).
10. Malkin, D. et al. Germline p53 mutations In a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
11. Srivastava, S., Zou, Z., Pirollo, K., Blattner, W. & Chang, E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749 (1990).
12. Malkin, D. p53 and the Li-Fraumeni Syndrome. Cancer Genet. Cytogenet. 66, 83-92 (1993).
13. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. & Kastan, M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. natn. Acad. Sci. U.S.A. 89, 7491-7495 (1992).
14. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the Cellular response to DNA damage.Cancer Res. 51, 6304-6311 (1991).
15. Kastan, M.B. et al. A mammalian cell cyde checkpoint pathway utilizing p53 and GADD45 is affective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
16. Yonish-Rouach, E. et al. Wild-type p53 Induces apoptosis of myeloid leukaemic cells that is inhibited by interieukin-6. Nature 352, 345-347 (1991).
17. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
18. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis In mouse thymocytes. Nature 362, 847-849 (1993).
19. Lee, J.M. & Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. natn. Acad. Sci. U.S.A. 90, 5742-5746 (1993).
20. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
21. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. & Elledge, S.J. The p21 cdk-lnteractlng protein cip1 Is a potent Inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
22. El-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumour suppression. Cell 75, 817-825 (1993).
23. Michalovitz, D., Halevy, O. & Oren, M., Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671-680 (1990).
24. Martinez, J., Georgoff, I., Martinez, J. & Levine, A.J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5, 151-159 (1991).
25. Farmer, G. et al. Wild-type p53 activates transcription in vitro. Nature 358, 83-86 (1992).
26. Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
27. Milner, J., Medcalf, E.A. & Cook, A.C. Tumour suppressor p53: Analysis of wild-type and mutant p53 complexes. Molec. Cell. Biol. 11, 12-19 (1991).
28. Milner, J. & Medcalf, E.A. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774 (1991).
29. Wolf, D., Harris, N. & Rotter, V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38, 119-126 (1984).
30. Shaulsky, G., Goldfinger, N. & Rotter, V. Alterations in tumour development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res. 51, 5232-5237 (1991).
31. Dittmer, D. et al Gain of function mutations in p53. Nature Genet. 4, 42-46 (1993).
32. Halevy, O., Michalovitz, D. & Oren, M. Different tumour-derived p53 mutants exhibit distinct biological activities. Science 250, 113-116 (1990).
33. Hinds, P.W. et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1, 571-580 (1990).
34. Chin, K.-V., Ueda, K., Pastan, I. & Gottesman, M.M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53.Science 255, 459-462 (1992).
35. Deb, S., Jackson, C.T., Subler, M.A. & Martin, D.W. Modulation of cellular and viral promoters by mutant p53 proteins found in tumour cells. J. Virol. 66, 6164-6170 (1992).
36. Lavigueur, A. et al. High incidence of lung, bone, and lymphold tumours In transgenic mice overexpressing mutant alleles of the p53 oncogene.Molec. Cell. Biol. 9, 3982-3991 (1989).
37. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
38. Hinds, P., Finlay, C. & Levine, A.J. Mutation is required to activate the p53 gene for cooperation with the ras oncogne and transformation. J. Virol. 63, 739-746 (1989).
39. Finlay, C., Hinds, P.W. & Levine, A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093.
40. Harvey, M. et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5, 225-229 (1993).
41. Jacks, T. et al. Tumour spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
42. Purdie, C. et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603-609 (1994).
43. Fearon, E. & Vogelstein, B. A genetic model for colorectal tumorigenesis.Cell 61, 759-767 (1990).
44. Kemp, C.J., Wheldon, T. & Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet. 8, 66-69 (1994).
45. Ory, K., Legros, Y., Auguin, C. & Soussi, T. Analysis of the most representative tumour-derived p53 mutants reveals that changes In protein conformation are not correlated with loss of transactivation or Inhibition of cell proliferation. EMBO J. 13, 3496-3504 (1994).
46. Prosser, J., Thompson, A.M., Cranston, G. & Evans, H.J. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.Oncogene 5, 1573-1579 (1990).
47. Li, B. et al. Preferential overexpression of a 172Arg-Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Diff. 5, 711-721 (1994).
48. Sehgal, P.B. & Margulies, L. Cell type and promoter dependent phenotype of p53 Val 135. Oncogene 8, 3417-3419 (1993).
49. Reed, K.C. & Mann, D.A. Rapid transfer of DNA from agarose gels to nylon membranes. Nucleic Acids Res. 13, 7207-7221 (1985).
50. Harvey, M. et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deflclent mice. Oncogene 8, 2457-2467 (1993).